UPSTREAM BIO INC
UPBNASDAQTrading Snapshot
- Day Range
- $640.54 – $655.73
- 52-Week Range
- $4.99 – $33.68
- Volume
- $1.89B
- Avg Volume
- $1.82B
- Shares Outstanding
- 54.4M
- Next Earnings
- Dec 5, 2026
Fundamentals Snapshot
- Annual Revenue
- $3M
- Last Q Revenue
- $773,000
- P/E Ratio
- -1.8
- P/S Ratio
- 88.6x
- EPS (TTM)
- $-2.87
- Dividend Yield
- 0.00%
- Dilution (1yr)
- +5.6%
Why Investors Own UPB
- ✓High-growth profile — revenue up +48.3% YoY with expanding US Equity exposure.
- ✓Healthy economics — 75% gross margin and 10% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
Execution delays, intensifying competition, and valuation compression if growth decelerates.
UPSTREAM BIO INC
UPB
StockOtter · stockotter.spaceAbout UPSTREAM BIO INC
Upstream Bio, Inc. is a biotechnology company in the clinical development stage, dedicated to innovating therapies for inflammatory conditions, particularly those affecting the severe respiratory system. Its pipeline notably features verekitug, a monoclonal antibody designed to selectively target and suppress the thymic stromal lymphopoietin receptor. Beyond this, the company is actively developing treatments for severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease. Established in 2021, Upstream Bio maintains its operational base in Waltham, Massachusetts.
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)Analyst Price Target
ⓘLatest News & Updates
These beaten-down stocks could bounce back in January, if history is any guide
Tax-loss selling is likely to lead these 20 stocks to become artificially depressed in the fourth quarter — and therefore good bets to bounce back in the new year
Upstream Bio Presents Results from the Phase 2 VALIANT Trial of Verekitug for the Treatment of Severe Asthma in Oral Presentation at ERS Congress 2026
– Verekitug, 100 mg dosed every 12 weeks, reduced AAER by 56% compared to placebo in patients with severe asthma – – Verekitug also delivered clinically meaningful improvements in lung function (FEV 1 ) and exhaled nitri
Upstream Bio Announces Pivotal Phase 3 Development Plans for Verekitug in Both Severe Asthma and CRSwNP
– Following productive FDA discussions, Upstream Bio will study 400 mg of verekitug administered every 12 weeks, versus placebo, in severe asthma and CRSwNP with one pivotal Phase 3 trial in each indication – – The Compa
Fannie Mae Announces Sale of Non-Performing Loans
Fannie Mae Announces Sale of Non-Performing Loans PR Newswire WASHINGTON, Aug. 19, 2026
Upstream Bio, Inc. (UPB) Reports Q2 Loss, Tops Revenue Estimates
Upstream Bio, Inc. (UPB) came out with a quarterly loss of $0.73 per share versus the Zacks Consensus Estimate of a loss of $0.78. This compares to a loss of $0.74 per share a year ago.
Upstream Bio, Inc. (UPB) Upgraded to Buy: What Does It Mean for the Stock?
Upstream Bio, Inc. (UPB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.